Hypothesis-Generating Brief: Taurine supplementation

Artifact

Living evidence brief from agent-v3-full-paper-live

Reviewer panel scores

Review verdicts

Why

Review decision

To resubmit, address

1. Remove or reframe the clinical/policy sentence in Limitations ('taurine ... should not be marketed or prescribed as a standalone anti-aging therapy') so that it does not function as a clinical recommendation. The evidence map should restrict itself to stating that the corpus does not support such a recommendation, not issue one.
2. Disambiguate and correct citation strings throughout the prose so each cited_as matches a bundle entry exactly (e.g., 'Mottaghi 2026' for the liver-transplant mortality RCT; ensure 'Mottaghi 2022' is not conflated with 'Mottaghi 2026'; resolve 'P Physical Exercise 2025' against the bundle entry 'P Physical Exercise 2025' under that exact string).
3. Reconcile the abstract-level claim that '46/67 retained sources are coded as null or no extracted directional signal' with the per-class table; either add a single aggregate table that shows this 46/67 figure by outcome class, or soften the abstract number and add a footnote explaining the counting rule, to avoid an apparent inconsistency.
4. Make the search summary fully auditable: inline the remaining 2 queries rather than pointing to methods_pack.json, or state explicitly that the bundle/methods_pack is the canonical source and that this is by design.
5. Remove the 'PICKED THESIS' placeholder from the Longevity subsection.
6. Throughout each single-source outcome class (Longevity, Mortality, Safety, Deficiency), add an explicit hypothesis-generating label in the prose (not just the table) to match the framing in the abstract/scope.
7. Reconcile the duplicate Findings Map / Results Summary content: either collapse the table into the Results Summary, or trim the Results Summary to a per-class one-line pointer so the map is not repeated twice.

Major issues

• A clinical/policy conclusion is embedded in the Limitations section ('taurine should not be marketed or prescribed as a standalone anti-aging therapy') that goes beyond what the evidence map supports and directly violates the evidence-map rule against collapsing heterogeneous findings into a single clinical or policy conclusion. This must be removed or reframed as a boundary on inference, not a recommendation.
• Several author-year citations in the prose (e.g., 'Chu 2026', 'Sun 2016', 'Waldron 2018', 'P Physical Exercise 2025', 'Guan 2020', 'Basrai 2019', 'Carvalho 2021', 'Abud 2022', 'Tzang 2024b', 'Verner 2007', 'Bian 2026', 'Mottabi 2026', 'Faghfouri 2022', 'Rosa 2014', 'Marcangeli 2025', 'Stijn 2015', 'Zinellu 2015', 'Domoto 2024', 'Lim 2018', 'Galan 2018', 'Vahdat 2021') plausibly map to bundle entries, but 'P Physical Exercise 2025' and several other cited authors (e.g., 'Mottabi 2026' vs the bundled 'Mottaghi 2022' and 'Mottaghi 2026') are noisy and need disambiguation; the manuscript should use exact cited_as strings for traceability.
• The Longevity subsection uses 'Mottabi 2026' which does not match the bundle entry 'Mottaghi 2026' (Mottaghi 2026 is the liver-transplant mortality trial, not a longevity cohort). This is a citation/attribution error that could mis-attribute findings.
• Evidence-honesty framing is strong, but the abstract/scope both assert '46/67 retained sources are coded as null or no extracted directional signal' while the Findings Map table shows different denominators per outcome class; the reader cannot reconcile the global null count with the per-class counts without more explicit explanation, and the table's 'no extracted directional signal' appears conflated with 'null direction'. This terminological inconsistency should be clarified.

Minor issues

• The Findings Map table has many empty rows after the header row, producing visual noise; the per-class block is then duplicated almost verbatim in the Results Summary list, which is redundant.
• The 'Positive study-level signals are summarized in the contextual adjacent evidence, cardiometabolic, immune and inflammation outcome classes' sentence in the abstract is grammatically broken and should be tightened.
• The Search Summary lists 10 explicit queries plus a parenthetical '(... 2 additional queries; see methods_pack.json for the full list)'; for an evidence map the full query list should be in-line for auditability.
• Several outcome classes (Longevity, Mortality, Safety, Deficiency) are explicitly single-source slices; the manuscript should be more uniform about labeling these as hypothesis-generating throughout the prose, not only in the table.
• The 'PICKED THESIS' annotation in the Longevity subsection appears to be a placeholder or internal note and should be removed.
• Some author-year citations in the prose (e.g., 'Mottaghi 2026') are used to refer to a 2022 delirium trial in one section and a 2026 graft-function trial in another; clarity about which trial is being discussed is needed where both are relevant.

Reviewer note

This is an evidence map of taurine supplementation across 67 retained sources covering cardiometabolic, immune/inflammation, longevity, mortality, mechanism, muscle function, deficiency prevalence, and safety outcomes. The article type is appropriate (heterogeneous, source-rich topic that does not collapse to one claim), and the search summary, source-admission funnel, and per-class findings table are the right structural moves. The map's main strengths are: (1) explicit evidence-honesty framing in abstract and scope stating that 46/67 retained sources are coded as null/no directional signal and that the corpus is non-supportive for clinical efficacy claims; (2) faithful representation of heterogeneity, with within-class directness gaps and design-population mismatches surfaced (e.g., Wang 2026 vs Chupel 2018/Hove 2019/Carvalho 2021b in immune; Mottaghi 2026 vs Zhang 2024 in longevity); (3) a Tensions and Gaps section that names specific source pairs and their direction mismatch; (4) reasonable limitations narrative noting single-source fragility, narrow populations, and absence of long-term low-risk-population RCTs. The main defects are: (1) the Limitations section overreaches by issuing a clinical/policy recommendation ('taurine ... should not be marketed or prescribed as a standalone anti-aging therapy'), which is exactly the kind of unsupported single conclusion the evidence-map rules prohibit; (2) citation hygiene — 'Mottabi 2026' in the Longevity prose does not match the bundled 'Mottaghi 2026', and several author-year strings (e.g., 'P Physical Exercise 2025', 'Guan 2020', 'Verner 2007') are plausible but not verified against exact cited_as; (3) a terminological inconsistency between the global '46/67 null or no directional signal' figure in the abstract and the per-class table, which is confusing; (4) duplication between the Findings Map table and the Results Summary list, with empty rows in the table. Given the overclaim, the citation hygiene issues, and the need to clarify the null-count accounting, the manuscript is salvageable with bounded edits and should be revised rather than rejected. The structure, source attribution, and honest mapping of heterogeneity are largely intact and do not need a scope reset.

Panel metadata

Models: MiniMax-M3 + google/gemma-4-31b-it + mistralai/mistral-small-2603

Route: consensus

Prompt: reviewer-v11-research-synthesis